Kenvue Inc. $KVUE Stock: ProShare Advisors LLC Lowers Stake

ProShare Advisors LLC lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 7.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,929,962 shares of the company’s stock after selling 701,219 shares during the quarter. ProShare Advisors LLC owned about 0.46% of Kenvue worth $157,703,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in KVUE. Vise Technologies Inc. raised its position in shares of Kenvue by 16.0% during the third quarter. Vise Technologies Inc. now owns 35,217 shares of the company’s stock valued at $622,000 after buying an additional 4,864 shares during the last quarter. Cidel Asset Management Inc. lifted its position in Kenvue by 5.4% during the 3rd quarter. Cidel Asset Management Inc. now owns 19,288 shares of the company’s stock worth $341,000 after acquiring an additional 988 shares during the period. Americana Partners LLC increased its holdings in shares of Kenvue by 3.7% during the 3rd quarter. Americana Partners LLC now owns 51,160 shares of the company’s stock valued at $903,000 after purchasing an additional 1,825 shares in the last quarter. North Dakota State Investment Board raised its position in shares of Kenvue by 2.8% during the 3rd quarter. North Dakota State Investment Board now owns 58,063 shares of the company’s stock worth $1,025,000 after purchasing an additional 1,558 shares during the last quarter. Finally, Generali Asset Management SPA SGR grew its position in shares of Kenvue by 5.4% in the third quarter. Generali Asset Management SPA SGR now owns 237,891 shares of the company’s stock valued at $4,201,000 after purchasing an additional 12,290 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on KVUE. Barclays raised their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. UBS Group dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Thirteen investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Trending Headlines about Kenvue

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Kenvue Trading Down 1.5%

NYSE KVUE opened at $19.26 on Friday. The stock has a market capitalization of $36.99 billion, a price-to-earnings ratio of 21.89, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a 52 week low of $14.06 and a 52 week high of $20.13. The stock’s 50 day moving average price is $18.40 and its two-hundred day moving average price is $18.19. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.

Kenvue (NYSE:KVUE) last issued its earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, hitting the consensus estimate of $0.29. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. During the same period in the previous year, the company posted $0.28 EPS. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is presently 96.55%.

Kenvue Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.